Navigation Links
Many high-risk Americans don't get hepatitis B vaccine
Date:1/19/2012

PROVIDENCE, R.I. [Brown University] Although there is an effective vaccine for hepatitis B and public health officials have a strong sense of who is at highest risk for the infectious liver disease, tens of thousands of people in the United States contract the virus every year. According to a new study by researchers at Brown University, missed opportunities to administer the vaccine continue to be a reason why infections persist.

"This is a really simple thing that we could do and if somebody ends up getting the disease because we didn't make the effort then I think that's really a shame," said Brian Montague, assistant professor of medicine in the Warren Alpert Medical School of Brown University and a physician at The Miriam Hospital.

Yet in an analysis published Jan. 12, 2012, in advance online in the journal Infection, senior author Montague and lead author Farah Ladak found that in a nationally representative sample of high-risk adults, 51.4 percent said they were unvaccinated. More than half of them had the potential to receive the vaccine based on their reported contact with health care providers.

The study is based on responses by more than 15,000 adults to the 2007 Behavioral Risk Factor Surveillance Survey, which gathers health information from more than 430,000 people across the United States. The respondents in the study's analysis acknowledged engaging in risk behaviors such as certain sexual practices or needle drug use and could definitively report their hepatitis B status. Previous research has found that more than 95 percent new infections in adults occur among people with such behavioral risk factors.

Montague, Ladak, and their co-authors sought to figure out who among this highly vulnerable population was going unvaccinated and whether and where they could have received the three required shots.

They found that vaccinations were relatively infrequent among adults older than 33 (vaccinations have increased markedly in children since the 1990s), among people with less access to health insurance, and among people who have also not been vaccinated against other diseases such as the flu.

But even among people with access to health care, including people who reported specific contact with health care providers, thousands of people went unvaccinated, Ladak said. The study identifies places where improved vaccine delivery would make a substantial difference for instance when people are tested for HIV, such as at the doctor's office, in a hospital or clinic, and especially in jail.

For those infected as adults, hepatitis B does not always result in persistent infection and chronic liver disease, but it is especially likely to do so among people infected with HIV. Such co-infections are common because many of the risk factors for contracting either virus are the same.

"In persons visiting [HIV-testing] locations there was a high prevalence of people who had not received the vaccine," said Ladak, a Brown public health graduate. "One of the areas that really stuck out was jails and prisons. Given that many states have mandates to vaccinate incarcerated individuals, you wonder why in so many of these prisons people have not received vaccinations."

Ladak noted that the new study's figures from 2007 closely mirror similar research published in 2000, suggesting that despite widespread awareness among public health officials that vaccinations have been lacking among adults, there has not been clear progress.

Calls to do better

The study lends additional support to the urging of the Institute of Medicine, which in a 2010 report emphasized the importance of seizing opportunities to vaccinate people for hepatitis B and C. The report suggested that officials have not devoted enough resources to vaccination programs, perhaps because the infections sometimes don't present any symptoms, as a reason for the continued prevalence of the diseases.

Montague said some programs are also structured to ensure missed opportunities. For example, funding for HIV care programs allows testing and vaccination of those who are HIV positive. Funding is often not available, though, for combined screening for hepatitis B together with HIV.

"Given that the risks for HIV, hepatitis B and hepatitis C overlap, what we need is integrated testing and prevention programs and strategies that link those cases identified with effective treatment in the community," Montague said.


'/>"/>
Contact: David Orenstein
david_orenstein@brown.edu
401-863-1862
Brown University
Source:Eurekalert  

Related biology news :

1. New MRI technique could mean fewer breast biopsies in high-risk women
2. Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists
3. Einstein receives high-risk/high-reward cancer research funding
4. NIH announces 115 awards to encourage high-risk research and innovation
5. Celebrex inhibited the burden of skin cancer in high-risk patients
6. Study links African ancestry to high-risk breast cancer
7. Electronic faucets unsafe for use in high-risk patient hospital settings
8. Zebrafish models identify high-risk genetic features in leukemia patients
9. Nanotech and synbio: Americans dont know whats coming
10. African-Americans aware and accepting, but often do not receive, the HPV vaccine
11. Many middle-aged and older Americans not getting adequate nutrition
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Many high-risk Americans don't get hepatitis B vaccine
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , ... a developer of innovative sensor-based diagnostic products, today announced the ... by new and existing investors.  Proceeds from the financing will ... Scanner , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... 3, 2016  With the growing need for ... is underway, therapies such as monoclonal antibodies, recombinant ... host of indications are in high demand. Conventionally ... development and production of these therapeutics. However, due ... high costs, novel approaches and novel expression systems ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier of ... North American healthcare market. , Aerocom Healthcare, LLC will be based in Denver, ... provide new pneumatic tube systems or expand existing systems within the U.S. and ...
Breaking Biology Technology: